Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Receivables: 2016-2023

Historic Change in Receivables for Summit Therapeutics (SMMT) over the last 6 years, with Sep 2023 value amounting to -$3,000.

  • Summit Therapeutics' Change in Receivables rose 99.76% to -$3,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.1 million, marking a year-over-year increase of 131.73%. This contributed to the annual value of -$359,000 for FY2023, which is 63.18% up from last year.
  • Summit Therapeutics' Change in Receivables amounted to -$3,000 in Q3 2023, which was up 50.00% from -$6,000 recorded in Q2 2023.
  • Summit Therapeutics' Change in Receivables' 5-year high stood at $3.5 million during Q3 2020, with a 5-year trough of -$3.7 million in Q4 2020.
  • Moreover, its 3-year median value for Change in Receivables was -$6,000 (2023), whereas its average is -$17,818.
  • Per our database at Business Quant, Summit Therapeutics' Change in Receivables skyrocketed by 3,953.40% in 2020 and then crashed by 499.12% in 2022.
  • Summit Therapeutics' Change in Receivables (Quarterly) stood at -$2.7 million in 2019, then crashed by 37.30% to -$3.7 million in 2020, then spiked by 74.76% to -$932,000 in 2021, then surged by 251.50% to $1.4 million in 2022, then surged by 99.76% to -$3,000 in 2023.
  • Its last three reported values are -$3,000 in Q3 2023, -$6,000 for Q2 2023, and -$350,000 during Q1 2023.